Latest Alcohol Alternatives News

The FDA’s recent ruling classifying traditionally prepared kava beverages as food under U.S. law clears a major regulatory hurdle for The Calmer Co, accelerating its growth on Amazon and strengthening its U.S. expansion strategy.

The Calmer Co. International Limited announces a leadership change with James S. Tonkin appointed Chairman as the company accelerates its U.S. market growth in natural kava products.

The Calmer Co (ASX – CCO) reported an impressive $8 million revenue for FY25, marking 86% year-over-year growth and positioning itself as a global leader in the emerging kava market. With expanding retail presence and strong US sales, the company is on track to break even in 2026.

The Calmer Co. has secured $700,000 in the first tranche of a $1.4 million convertible note raise, welcoming US distributor Applied Food Sciences as a strategic investor to fuel its expanding wholesale presence.

The Calmer Co. International Limited has reported an 81% surge in retail sales through Coles in July, driven by a significant expansion in store presence and strong consumer demand for its natural relaxation products.

The Calmer Co. International Limited has reported a striking 86% revenue jump to over AU$8 million in FY25, propelled by diversified sales channels and a strategic US expansion highlighted by new flavoured kava shots launched exclusively on Amazon USA.

The Calmer Co. has secured a major retail milestone by launching its Fiji Kava 50g Instant Kava product across Woolworths supermarkets nationwide, significantly broadening its Australian footprint.

The Calmer Co. International Limited has significantly expanded the distribution of its flagship kava products in Coles supermarkets, reflecting growing consumer appetite for natural relaxation alternatives to alcohol.

The Calmer Co. International Limited has successfully closed a renounceable rights issue, raising just over $1 million and issuing hundreds of millions of new shares and options. Directors’ strong participation signals confidence as the company prepares for growth.

Althea Group Holdings reported $5.02 million in Q3 FY25 receipts, driven by strong growth at Peak Canada and the launch of Peak USA, while its pharmaceutical cannabis division faces steep revenue declines prompting strategic review.